or Try an Advanced Search...

    Tyrosine Kinase Receptors Stocks List

    Symbol Grade Name % Change
    BPMC B Blueprint Medicines Corporation 1.91
    ERAS C Erasca, Inc -1.52
    PBYI C Puma Biotechnology Inc 2.11
    NUVL C Nuvalent, Inc. 1.71
    VOR D Vor Biopharma Inc. 0.16
    ELVN D Enliven Therapeutics, Inc. -0.08
    ZNTL F Zentalis Pharmaceuticals, Inc. 1.60
    BBIO F BridgeBio Pharma, Inc. 0.87
    TYRA F Tyra Biosciences, Inc. -3.21
    BDTX F Black Diamond Therapeutics, Inc. 0.00
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Cancer Biopharmaceutical Epidermal Growth Factor Receptor Fibroblast Growth Factor Receptor Protein Kinase Inhibitor Biotechnology Enzymes Fibroblast Growth Factor Her2 Preclinical Stage Biopharmaceutical Solid Tumors Therapies For Cancer Tumor Tyrosine Kinase Achondroplasia Acute Myeloid Leukemia Advanced Solid Tumors Amyloid Amyloidosis Anaplastic Lymphoma Kinase

    Related ETFs - A few ETFs which own one or more of the above listed Tyrosine Kinase Receptors stocks.

    Symbol Grade Name Weight
    CNCR F Loncar Cancer Immunotherapy ETF 1.46
    LRNZ A TrueMark Technology, AI & Deep Learning ETF 0.8
    CANC D Tema Oncology ETF 0.69
    BBC F Virtus LifeSci Biotech Clinical Trials ETF 0.57
    SCDS B JPMorgan Fundamental Data Science Small Core ETF 0.28
    View all Tyrosine Kinase Receptors ETFs...
    Compare ETFs
    Compare CANC to BBC Compare CANC to SCDS Compare LRNZ to CANC

        Tyrosine Kinase Receptors Stocks Recent News

        Date Stock Title
        Nov 21 BBIO Why Is BridgeBio Pharma, Inc. (BBIO) Among the Worst Performing Biotech Stocks in 2024?
        Nov 21 PBYI PBYI Begins Phase II Study on Alisertib Combo in Breast Cancer
        Nov 21 PBYI Puma commences Phase II trial of alisertib for breast cancer treatment
        Nov 20 PBYI Puma Biotechnology Announces Initiation of ALISCA™-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
        Nov 19 BBIO BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market
        Nov 19 BBIO The Consensus EPS Estimates For BridgeBio Pharma, Inc. (NASDAQ:BBIO) Just Fell Dramatically
        Nov 18 BBIO Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months
        Nov 18 BBIO BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia
        Nov 15 BPMC Blueprint Medicines' Growth With AYVAKIT And Next-Gen Oncology Drugs
        Nov 15 ERAS Erasca (ERAS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
        Related Industries: Biotechnology
        Related Stock Lists: Biopharmaceutical Solid Tumors Advanced Solid Tumors Antibodies Biotechnology Blastoma Cancer Cancer Immunotherapy Drug Discovery Enzymes Epidermal Growth Factor Receptor Fibroblast Growth Factor Fibroblast Growth Factor Receptor Glioblastoma Glioblastoma Multiforme Lymphoma Metastatic Solid Tumors Pharmacy Phosphoinositide 3 Kinase Inhibitor Precision Medicine
        Tyrosine Kinase Receptors

        Tyrosine kinase receptors are a type of cell surface receptor that binds to specific molecules and activates a signal transduction pathway inside the cell. They are involved in a wide range of cellular processes, including cell growth, differentiation, and migration. They are also involved in the regulation of the immune system and in the development of cancer.

        Browse All Tags